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 24 
Abstract  25 
The present study describes the virological and serological profiles of PCV2 vaccinated (V) and non-26 
vaccinated (NV) piglet subpopulations coming from V and NV sows in a PCV2 subclinically infected 27 
farm. Four hundred seventy-six piglets born from V or NV sows were further subdivided in a total of four 28 
groups: NV sows-NV pigs (NV-NV), NV sows-V pigs (NV-V); V sows-NV pigs (V-NV) and V sows-V 29 
pigs (V-V). Seventy-five pigs were randomly selected at the beginning of the trial from each group and 30 
they were bled at 4, 8, 12, 16, 21 and 25 weeks of age. All animals included in the trial were weighed at 4 31 
and 25 weeks of age and their average daily weight gain (ADWG) was calculated. Serum samples 32 
obtained at different time points were used to assess PCV2 infection (viremia) and the level of antibodies 33 
by means of immunoperoxidase monolayer assay (IPMA) against this pathogen. IPMA titres (classified in 34 
high, medium or low) and PCR results (positive or negative) were analyzed using a multiple 35 
correspondence and K-means cluster analysis. According to these tests, animals included in the study 36 
were classified into the following four clusters: 1) 93 piglets that were viraemic mainly from 12 to 25 37 
weeks of age and with PCV2 antibody titers increasing over time; 2) 75 piglets with late PCV2 infection 38 
and seroconversion (later than 16 weeks of age); 3) 26 piglets with high but decreasing PCV2 antibody 39 
titers and low percentages of PCV2 PCR positive serum samples; and 4) 105 piglets with medium and 40 
high IPMA titers throughout the trial and sporadic PCR positive samples. The defined subpopulations of 41 
piglets were observed in all experimental groups (NV-NV, NV-V, V-NV and V-V) although in variable 42 
percentages. Thus, animals from clusters 1 and 2 belonged mainly to the NV-NV and V-NV groups and 43 
animals from clusters 3 and 4 were distributed mainly into the NV-V and V-V groups. Finally, the 44 
ADWG of pigs belonging to clusters 3 and 4 was significantly higher (p=0.02) than that of pigs belonging 45 
to clusters 1 and 2. Within each cluster, no statistically significant differences were found in ADWG 46 
between treatment groups.  47 
 48 
Key words: Porcine circovirus type 2 (PCV2); vaccination; sow; piglet; individual variation; average 49 
daily weight gain; subpopulations 50 
51 
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1. Introduction 52 
Porcine circovirus type 2 (PCV2)-systemic disease (SD) is considered one of the major swine diseases 53 
worldwide. Infection with PCV2 is a necessary but not sufficient condition for pigs to develop the 54 
disease. Thus, management factors are important for disease development (Woodbine et al., 2007, 55 
Alarcon et al., 2011) and secondary pathogens, such as Mycoplasma hyopneumoniae, porcine 56 
reproductive and respiratory syndrome virus (PRRSV) and porcine parvovirus (PPV), are also considered 57 
infectious risk factors for disease triggering (Opriessnig et al., 2004). Traditionally, PCV2-SD control was 58 
based on counteracting infectious and non-infectious triggering factors, such as management 59 
improvement, control of co-infections and changes of the boar genetic background (Grau-Roma et al., 60 
2011). However, PCV2 vaccines have demonstrated to be very efficient to control PCV2-SD and PCV2 61 
infections under experimental and natural conditions (Beach and Meng, 2012). 62 
 63 
PCV2 vaccines can be applied in sow and /or in piglets (Grau-Roma et al., 2011). PCV2 sow (and/or gilt) 64 
vaccination leads to an increase of PCV2 antibody titres in sow serum, a reduction in viremia as well as 65 
viral shedding in milk and colostrum and an improvement of piglet production records (mortality rates 66 
and average daily weight gain [ADWG]) (Gerber et al., 2011; Kurmann et al., 2011). Piglet PCV2 67 
vaccination results in a significantly reduction of viral-induced microscopic PCV2-SD lymphoid lesions, 68 
decrease mortality and cull rates, decrease the frequency of co-infections and improve ADWG (Segalés et 69 
al., 2009, Martelli et al., 2011). Indeed, a meta-analysis study of 66 published field trials found a positive 70 
effect of all PCV2 commercially available vaccines on productivity, with no statistically significant 71 
differences among them (Kristensen et al., 2011). Alternatively, a not yet extensively studied strategy is 72 
the double (sow and piglet) PCV2 vaccination (Opriessnig et al, 2010, Pejsak et al, 2010, Fraile et al, 73 
2012a). This strategy achieved the best productive results although no statistically significant differences 74 
were observed in comparison with a protocol based only in piglet vaccination (Fraile et al 2012a). On the 75 
other hand, a recent publication (Oh et al., 2014) confirmed that the combination of sow and pig (at 49 76 
days of age) vaccination significantly reduced PCV2 viremia, induced higher neutralizing antibody titres, 77 
and resulted in higher proportion of CD4(+)CD8(+)IFN-γ(+) lymphocyte subsets in piglets compared to 78 
the other groups of animals tested (non-vaccinated piglets coming from vaccinated sows, only vaccinated 79 
piglets at 21 or 49 days of age, and piglets vaccinated at 21 days of age coming from vaccinated sows). 80 
Thus, the combination of sow and pig (49 days of age) vaccination could be more effective for controlling 81 
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PCV2 infection if PCV2 the infection occurs during the growing-finishing period in herds. From an 82 
economical perspective, PCV2 vaccination is considered a worldwide great success. However, these 83 
vaccines are imperfect in the sense that they prevent clinical signs but not infection (Kekarainen et al., 84 
2010). Moreover, the seroconversion elicited by the vaccine can be affected by the antibody titres (Fraile 85 
et al 2012a,b) and the vaccine efficacy may depend on the timing of natural infection (Beach and Meng, 86 
2012). As a consequence, in a PCV2 vaccinated community, subpopulations of animals not equally 87 
protected in front of a natural PCV2 challenge may exist. Optimization of PCV2 vaccination protocols 88 
would probably require a better characterization of piglet subpopulations coming from piglet, sow or both 89 
vaccination programs. To the authors’ knowledge, this kind of information is not yet available in the 90 
literature. Thus, the main goal to this research work was to characterize, by means of PCV2 antibody and 91 
virological profiles, the different piglet subpopulations generated by piglet and/or sow vaccination. A 92 
secondary objective was to describe the ADWG observed in the different piglet subpopulations. 93 
 94 
2. Material and methods 95 
2.1. Study design 96 
Data analysed in this study was taken from a previously published field study (Fraile et al., 2012a). 97 
Briefly, the study was conducted in a 1500-sow Spanish farm with clinical history of PCV2-SD in which 98 
no PCV2 vaccination had been ever used. Pigs included in the study were born from Landrace (50%) x 99 
Large white (50%) sows mated with Pietrain (100%) boars. One month before the beginning of the trial, 100 
PCV2-SD was diagnosed (fulfilling the internationally accepted disease case definition) (Segalés et al., 101 
2005) in 5 out of 10 animals showing a wasting condition. One week before mating, a population of 57 102 
sows was distributed into two groups: vaccinated (V, n=26) and non-vaccinated sows (NV, n=31). V 103 
sows received 2 ml of Porcilis
®
 PCV (MSD Animal Health, The Netherlands) and NV received 2 ml of 104 
phosphate buffer saline (PBS). The parity average was not significantly different between V (3.1) and NV 105 
(3.2) sows; animals with different treatments were mingled in the same farrowing and gestation units. 106 
Blood samples were taken from the sows 2 weeks pre-mating and at 3, 10 and 17 weeks post-mating. All 107 
healthy piglets (n=476) born from these 57 sows were included (at 4 weeks of age) in a sow and/or piglet 108 
vaccination strategy as follows: NV sows-NV pigs (NV-NV, n=134), NV sows-V pigs (NV-V, n=135); V 109 
sows-NV pigs (V-NV, n=104) and V sows-V pigs (V-V, n=103). The housing and husbandry conditions 110 
were standard for pigs reared under intensive conditions in Spain. Briefly, animals were housed in 111 
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confinement with controlled environmental conditions (temperature and ventilation). In particular, cross-112 
fostering was not allowed for the litters under study and the weaning age was close to 4 weeks of age 113 
(27+2 days). At weaning, V piglets received 2 mL of Porcilis
®
 PCV by intramuscular route and NV ones 114 
received 2 mL of PBS by the same route. Piglets with different treatment were mingled in the same 115 
growing and finishing units. Mortality during the study was recorded. No evidence of PCV2-SD was 116 
observed in the studied batch. The sampling size of the study was carried out to be able to detect 117 
differences in ADWG close to 20 g/day between vaccinated and non-vaccinated piglets (Fraile et al, 118 
2012a). Nevertheless, the final number of piglets included in this study allowed having statistical power 119 
to detect differences between the proportion of the piglets presents in the different groups equal or higher 120 
than 15%. 121 
 122 
From each treatment, a group of seventy-five pigs was randomly selected and bled at 4 (27±2 days of 123 
age), 8, 12, 16, 21 and 25 weeks of age. In addition, these animals were weighed at 4 and 25 weeks of age 124 
and their ADWG was calculated. Data analysis was done considering these 75 pigs per treatment group. 125 
This number of animals allowed describing precisely the virological and serological profile for each 126 
treatment. Treatments, housing, husbandry and slaughtering conditions conformed to the European Union 127 
Guidelines and Good Clinical Practices, and were identical for all experimental groups. 128 
 129 
 130 
2.2. PCR to detect PCV2 nucleic acid 131 
Serum samples were processed by standard PCV2 PCR (Quintana et al., 2002). In the statistical analyses, 132 
a variable including PCR result (positive or negative) and sampling week was generated. Thus, variable 133 
PCRXS or PCRWX represented PCR results of sows at X weeks pre- or post-mating, and PCR results of 134 
piglets at X weeks of age, respectively.  135 
  136 
2.3. Serology to detect PCV2 antibodies 137 
Presence of antibodies against PCV2 were tested using immunoperoxidase monolayer assay (IPMA) 138 
(Rodríguez-Arrioja et al., 2000). IPMA results were expressed as log2 titre values. Animals were 139 
classified taking into account their antibody titre as low (<10 log2 IPMA titers), medium (between 10 and 140 
12 log2 IPMA titres) or high (>12 log2 IPMA titres). 141 
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 142 
2.4. Statistical analysis 143 
Statistical analyses were carried out using the SAS system V.9.2 (SAS institute Inc, Cary, NC, USA) and 144 
the SPAD v5.0, C.I.S.I.A., Saint Mandé, France. For all analyses, the individual pig was considered as the 145 
experimental unit. The significance level (α) was set at 0.05. 146 
 147 
2.4.1. Multiple correspondence analysis 148 
Multiple correspondence analysis (MCA) is a multivariate, descriptive and exploratory technique that is 149 
used to visualize relationships within a set of categorical variables (Greenacre et al, 2006), without any 150 
dependent variable or assumptions on data distribution. This technique was carried out to summarize the 151 
values of piglet IPMA (low, medium, high) and piglet PCV2 detection by PCR in serum (positive or 152 
negative) at each sampling time. 153 
 154 
The remaining variables (piglet and/or sow PCV2 vaccination and IPMA and PCR results in sows at each 155 
sampling time) were included in the analysis as supplementary variables. In a MCA analysis, these 156 
variables were not used in determining the locations of the other, but were displayed on the output and 157 
helped in the interpretation of the active variables (PCR and IPMA in piglets).  158 
 159 
In the MCA output, relationships between different categories of the selected variables are typically 160 
represented as points in a two-dimensional space; the first and second dimensions are represented in the X 161 
and Y axes of the graph, respectively. Supplementary variables are represented in different symbol and 162 
color than the active ones. The size of the categories of the active variables is proportional to the number 163 
of observations within this category. The plot can be interpreted by considering which variable categories 164 
are plotted closely together; relatedness between variables is considered in both the 1
st
 dimension along 165 
the X axis, and in the 2
nd 
dimension along the Y axis. The distance of an object from the origin of the plot 166 
reflects variation from the "average response pattern", which relates to the most frequent category for 167 
each variable. Thus, objects with many characteristics corresponding to the most frequent categories will 168 
be near the origin of the axes (X=0, Y=0). In contrast, objects with unique characteristics are located far 169 
from the origin of the axes. For example, the most frequent combinations between piglet IPMA (low, 170 
medium or high) and PCR results (positive or negative) were plotted close to each other, whereas those 171 
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rare combinations were plotted further apart (Ribbens et al, 2008). For each variable and in each 172 
dimension, a discrimination measure is computed and compared using bivariate t-tests. This measure can 173 
be regarded as squared component loading and it is also the variance of the quantified variable in the 174 
dimension. Finally, with the MCA analysis, it will be also generated factors (combination of variables) to 175 
explain the whole observed variance. 176 
 177 
2.4.2. Cluster analysis 178 
The K-means cluster analysis is a multivariate method used to divide the heterogeneous group of piglets 179 
into homogeneous subgroups using non-hierarchical methods, via an iterative process that continues until 180 
the sum of squares to the assigned cluster centres is minimized. A K-means cluster analysis (Lebart, et al, 181 
2000) was conducted to reveal populations of piglets with similar IPMA and PCR results based on the 182 
factors derived from the MCA. The clusters obtained are represented in a tree dendrogram (Hartigan, 183 
1975). 184 
 185 
The distribution of the experimental groups (NV-NV, NV-V, V-NV and V-V) within each cluster was 186 
analysed using a chi-squared test. Finally, An ANOVA test was used to compare the production 187 
performance (ADWG) between clusters and, within each cluster, the ADWG was also compared taking 188 
into account the experimental group as explanatory variable (NV-NV, NV-V, V-NV, V-V). 189 
 190 
 191 
3. Results 192 
3.1. Multiple correspondence analysis  193 
The results of the MCA analysis are represented in Figure 1. The total variance explained by this analysis 194 
was 29.8%; with 16.5% explained by the 
1st
 dimension and 13.3% by the 2
nd
 dimension, respectively. 195 
Discrimination measures provided insight into the influence exerted by each variable in order to explain 196 
the variance observed in each dimension. Variables with the highest discrimination values are included in 197 
Table 1.  198 
The 1
st
 dimension (X axis) separates PCR positive (X<0) from PCR negative animals (X>0). On the left 199 
side of 1
st
 dimension, positive PCR results at weeks 16, 21 and 25 were close to (and therefore associated 200 
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with) low values of IPMA at weeks 8 and 12, and high values of IPMA at weeks 21 and 25 due to its 201 
proximity in the plot. On the right side of the 1
st
 dimension, there were higher values of IPMA at weeks 8 202 
and 12. When supplementary variables were considered, the left side of this plot was dominated by NV 203 
piglets. On the contrary, the right side of the 1
st
 dimension contained variables that were mainly 204 
associated with V piglets.  205 
The 2
nd
 dimension (Y axis) provides insight into early PCV2 detection by PCR (Y < 0 in the plot). Thus, 206 
PCR positive animals at weeks 8 and 12 have Y values less than -0.76. Such early infection was 207 
associated with lower values of IPMA at weeks 4 and 8 and higher values at weeks 16 and 21 (see the 208 
proximity in the plot between these parameters). When considering supplementary variables, lower 209 
quadrants were associated to viral detection by PCR in sows at weeks 10 and 17 post-mating and low 210 
IPMA values in sows at 10 weeks post-mating. The top (not early PCV2 detection in piglets) and bottom 211 
side of the plot is dominated by V and NV sows, respectively. 212 
3.2.- Cluster analysis 213 
The cluster analysis was performed considering the most significant 10 factors (combination of variables) 214 
obtained from the MCA analysis (which accounted for 77% of variance explained). Results are presented 215 
in a tree dendrogram (Figure 2) and in pie charts (Figure 3). The first division separates two groups of 216 
animals which were associated with the vaccination of the piglets: in the first group (A) there were most 217 
of the NV pigs (92%), whereas in the second group (B) most of the V ones (80.5%). Each one of these 218 
groups could be subdivided into two smaller groups, which were associated with both sow and piglet 219 
vaccination (Figure 3). Most of the piglets from the NV-NV group were included in clusters 1 and 2, with 220 
few animals in cluster 4. However, most of the piglets belonging to the V-V group were included in 221 
clusters 2, 3 and 4, with few pigs in cluster 1. On the other hand, most of the piglets of the V-NV group 222 
were included in clusters 2, 1 and 3, with few animals in cluster 4. Finally, most of the piglets of the NV-223 
V group were included in clusters 4, 3 and 1, with few animals in cluster 2. 224 
 225 
3.3.- Association of the clusters with PCR and IPMA values 226 
The individual and average PCV2 antibody profiles and the percentage of PCV2 PCR positive animals of 227 
each cluster throughout the trial are described in Figure 4 (black and blue lines for individual and average 228 
values, respectively). The obtained clusters were the following: 1) 93 piglets (31%) that were viraemic 229 
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mainly from 12 to 25 weeks of age and with PCV2 antibody titers increasing over time (from 12 to 25 230 
weeks of age); 2) 75 piglets (25%) with late PCV2 infection (later than 16 weeks of age) as well as 231 
seroconversion; 3) 26 piglets (9%) with high but decreasing PCV2 antibody titers and low percentages of 232 
PCV2 PCR positive serum samples; and 4) 105 piglets (35%) with medium and high IPMA titers 233 
throughout the trial and sporadic PCR positive samples. Finally, one piglet could not complete the trial 234 
and was excluded of the analyses. 235 
 236 
3.4.- Association of the clusters to ADWG 237 
The comparison of the ADWG of animals included in each clusters is detailed in Table 2. ADWG of pigs 238 
belonging to clusters 3 and 4 was significantly higher (p=0.02) than that of pigs belonging to clusters 1 239 
and 2. Within each cluster, no statistically significant differences were found between the ADWG taking 240 
into account the experimental group (NV-NV, NV-V, V-NV, V-V) as explanatory variable.  241 
 242 
 243 
Discussion 244 
The vaccine used in this trial is licensed for piglets only, and therefore its use in sows was off label. A 245 
single dose of vaccine applied to piglets at weaning (independently of sow treatment) caused lower 246 
percentages of PCV2 infected pigs over the production period and a significant improvement of 247 
production parameters in comparison with non-vaccinated piglets (Fraile et al, 2012a). These results are 248 
in agreement with other studies already published testing one (Takahagi et al., 2010; Martelli et al., 2011) 249 
or two (Takahagi et al., 2010; Lyoo et al., 2011) doses of the same vaccine. In the present work, in which 250 
all the different vaccination protocols were compared contemporaneously (NV-NV, NV-V, V-NV and V-251 
V) in a farm that never vaccinated before, the double PCV2 vaccination (sow and piglet) reduced the 252 
percentage of PCV2 infected pigs and reported also the best production parameters (although not 253 
significantly different from those of vaccinated pigs coming from non-vaccinated sows, NV-V group) 254 
(Fraile et al, 2012a). On the other hand, different subpopulations of piglets were detected in all 255 
experimental groups (NV-NV, NV-V, V-NV and V-V). This situation means that, in spite of the different 256 
vaccination treatments, there were a variable proportion of subpopulations of animals within each 257 
treatment. 258 
 259 
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Vaccination is one of the most efficient ways to prevent and control infectious diseases. However, 260 
vaccine efficacy for many diseases almost never reaches a value of 100% (Thursfield, 1997). Such 261 
vaccine “imperfection” was highlighted in the present study by the fact that a low percentage of 262 
vaccinated piglets, coming from vaccinated or non-vaccinated sows (NV-V and V-V), were viraemic 263 
mainly from 12 to 25 weeks of age and with PCV2 antibody titers increasing over the same period 264 
(cluster 1). Thus, the virological and serological profiles in this subpopulation of vaccinated piglets were 265 
similar to the virological and serological profiles observed in non-vaccinated ones. There are different 266 
reasons that could explain this finding. The first one could be a wrong application of the vaccine. This 267 
possibility is hardly probable in this case because animals were vaccinated using good clinical practices 268 
by experienced veterinarians. Another possible explanation could be the genetics of these piglets. The 269 
relationship of host genetics to responsiveness against vaccines has not been greatly explored, but it is 270 
likely to involve the major histocompatibility complex MHC (e.g. processed peptides may not bind or 271 
only bind at low affinity to particular alleles) and genes controlling cytokine profiles (e.g. Th1 versus 272 
Th2) or levels of proinflammatory cytokines. Such genes could account for low or non-responsiveness to 273 
vaccines (Glass, 2004). In fact, detection of “high” versus “low” responders in terms of cellular immunity 274 
measured as PCV2 specific IFN- secreting cells upon natural PCV2 infection has been described 275 
(Martelli et al., 2011). Therefore, it would not be surprising that host genetics would modulate the 276 
immune response mounted against PCV2 vaccination. Finally, lack of expected response to PCV2 277 
vaccination could be attributed to interference with maternally derived immunity. Thus, interference with 278 
the efficacy on the PCV2 vaccine might depend on the level of maternally derived antibodies (MDA) at 279 
the time of vaccination. Animals with IPMA titers equal or beyond 10 log2 show interference with the 280 
development of the humoral immune response after vaccination, while piglets with levels below 8 log2 do 281 
not show interference (Fort et al., 2009, Martelli et al., 2011; Fraile et al., 2012a,b). In contrast, it has 282 
been demonstrated that, even in the presence of high levels of MDA, piglets immunized with PCV2 283 
vaccines respond to vaccination with a significantly reduced viremia, number of PCV2 PCR positive pigs 284 
and mortality rate, and a significantly greater ADWG than those of the NV animals (Fraile et al., 285 
2012a,b). In the present case, there was no association between the subpopulation of V piglets that 286 
seemed not to respond efficiently to vaccination and a high PCV2 antibody titer transferred by their dam 287 
through colostrum. This result reinforces that the possible interference between MDA and the response to 288 
PCV2 vaccination in piglets is probably of low relevance in terms of vaccine efficacy if vaccination is 289 
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applied later than 3 weeks of age as recommended by vaccine manufacturers (summary of product 290 
characteristics of PCV2 vaccines). 291 
 292 
On the other hand, a small subpopulation of NV animals coming from NV sows showed medium and 293 
high IPMA titers throughout the trial and sporadic PCR positive samples (cluster 3). Moreover, these 294 
animals showed an excellent growth performance. Thus, these NV piglets resembled the V ones in terms 295 
of virological, antibody dynamics and production performance. There are two main reasons that could 296 
explain this apparent resistance to PCV2 infection. Firstly, it may happen that these animals did not get 297 
PCV2 infection throughout the trial but this possibility is hardly probable since PCV2 infection, either by 298 
PCR detection or seroconversion during the study period, was demonstrated in all the animals. Another 299 
potential explanation could be again the genetic background of these piglets as it has been stated above. 300 
In fact, it has been published that genetics plays a major role in respect to susceptibility or resistance to 301 
PCV2-SD clinical expression under field conditions (Lopez-Soria et al, 2011). This observation is 302 
consistent with other pig diseases such as porcine reproductive and respiratory syndrome virus (PRRSV). 303 
Thus, there has emerged a body of evidence associating host genetics with different outcomes following 304 
viral infections. As an example, pigs from lines or breeds with improved reproductive traits (Meishan and 305 
Large White) are more resistant to the effects of the PRRS virus than pigs from lines selected for lean 306 
growth rate (Duroc and Pietrain) (Petry et al, 2007; Reiner et al, 2010). In general terms, genetic variation 307 
in host resistance to infectious disease is ubiquitous (Bishop et al, 2005), but identifying genes or 308 
pathways that determine viral disease resistance/susceptibility is a complex process (Bishop and 309 
MacKenzie, 2003). Although pathways and mechanisms involved in specific disease/infection-resistance 310 
traits have not yet been fully characterized, genetic variation in disease resistance/susceptibility is likely 311 
to be polygenic, regulating aspects of both innate resistance and acquired immunity. So far, genomic 312 
regions that could be involved in the genetic resistance to PCV2-SD are not known. 313 
 314 
The rationale of vaccinating sows is based on increasing PCV2 antibody titres in sow serum and reducing 315 
viremia as well as viral shedding in milk and colostrum (Gerber et al., 2011, Kurmann et al., 2011). 316 
Moreover, PCV2 antibody titres in piglets coming from V sows are higher compared to piglets coming 317 
from NV ones (Sibila et al., 2013). This vaccination strategy could be an efficient way to control PCV2-318 
SD but it is critical to ensure enough colostrum intake during the first 24 hours of life. According to 319 
12 
 
obtained results, all 4 different subpopulations (clusters) were fairly well represented in the V-NV group 320 
of pigs. A plausible rationale for this observation in the first cluster (viraemic mainly from 12 to 25 weeks 321 
of age and with PCV2 antibody titers increasing over time) could be explained by a low colostrum intake 322 
during the lactation period with an early PCV2 infection, as suggested by Grau-Roma et al. (2011). In 323 
contrast, the second cluster (late PCV2 seroconversion) could be explained by a good colostrum intake 324 
that prevented an early PCV2 infection. Finally, the presence of animals belonging to the third (high but 325 
decreasing PCV2 antibody titers and low percentages of PCV2 PCR positive serum samples) and fourth 326 
clusters (medium and high IPMA titers throughout the trial and sporadic PCR positive samples) could be 327 
partially explained, as detailed before, by the individual genetic background of the pigs in terms of PCV2 328 
disease/infection resistance. 329 
  330 
In conclusion, the present study describes four subpopulations of V and NV pigs coming from V and NV 331 
sows according their serological and virological status. Those different profiles were variably represented 332 
in all the experimental groups, but the best serological/virological outcomes were mainly composed by 333 
vaccinated piglets (coming from V and NV sows). It is very likely that these subpopulations would be 334 
represented in all PCV2 vaccinated farms, although the different farm conditions, vaccination regimes, 335 
and piglet management during lactation may affect the proportion of pigs in each cluster. 336 
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Figure Legend 477 
 478 
Figure 1. Multiple correspondence analysis. The plot is interpreted by considering which variable 479 
categories are plotted closely together; relationship between variables is considered in both the 1
st
 480 
dimension along the X axis, and in the 2
nd 
dimension along the Y axis. The 1
st
 dimension (X axis) 481 
separates PCR positive (X<0) from PCR negative animals (X>0). The 2
nd
 dimension (Y axis) provides 482 
insight into early PCV2 detection by PCR (Y < 0 in the plot). Supplementary variables are represented in 483 
different symbol and color than the active ones. The size of the categories of the active variables is 484 
proportional to the number of observations within this category. 485 
 486 
Figure 2. K-means cluster analysis using non-hierarchical methods providing homogeneous subgroups of 487 
animals according to PCV2 IPMA and PCR similarities. The clusters are represented in a tree 488 
dendrogram, and percentages indicate the number of pigs belonging to each of these subpopulations. 489 
 490 
Figure 3. Distribution of the piglets within each cluster taking into account the experimental group (NV 491 
sows-NV pigs (NV-NV), NV sows-V pigs (NV-V); V sows-NV pigs (V-NV) and V sows-V pigs (V-V)). 492 
 493 
Figure 4. PCV2 antibody titre (A) and the percentage of PCV2 serum positive animals by PCR (B) 494 
depending on the cluster throughout the trial. It is represented all the animals (black lines) and the average 495 
value for each week in each cluster (blue line). 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
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Table 1 Discrimination measures of variables that were used in the multiple correspondence analysis. 508 
These values correspond to a Student’s t distribution (absolute values greater than 2 are statistically 509 
significant). 510 
 Discrimination measure 
Variable 1
st
  
Dimension  
2
nd
 
Dimension  
Low IPMA4 NS -8.55 
High IPMA4 NS 10.02 
Low IPMA8 -7.80 -5.58 
Med IPMA8 NS 8.29 
High IPMA8 9.66 -3.23 
Low IPMA12 -8.67 NS 
Med IPMA12 -4.27 4.62 
High IPMA12 11.05 -5.64 
Low IPMA16 -6.76 10.41 
Med IPMA16 4.16 NS 
High IPMA16 NS -11.45 
Low IPMA21 NS 8.43 
Med IPMA21 9.01 NS 
High IPMA21 -6.95 -5.05 
Low IPMA25 4.51 6.53 
Med IPMA25 8.35 NS 
High IPMA25 -9.53 NS 
PCR8 NS -5.64 
PCR12 NS -9.69 
PCR16 -8.34 -4.47 
PCR21 -9.40 NS 
PCR25 -10.45 NS 
NS= Not significant511 
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Table 2. Average daily weight gain (Kg/day), SE and confidence interval (95%) calculated for pigs from 512 
4 to 25 weeks of age taking into account the cluster they belong to. 513 
 514 
Cluster Average SE Confidence interval (95%) 
   Lower limit Upper limit 
1 0.62
b
 0.008 0.60 0.63 
2 0.60
b
 0.008 0.58 0.61 
3 0.64
a
 0.014 0.61 0.66 
4 0.63
a
 0.007 0.61 0.64 
 515 
Different superscript means statistically significant differences between clusters (p<0.05). 516 
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Figure 1.  1 
 2 
Blue variables: Used in the MCA analysis 3 
Green variables: Supplementary variables that have not affected the MCA results. 4 
PCRW4 was a supplementary variable because only four animals were PCV2 PCR positive at this age 5 
and it could not be included in the MCA analysis. 6 
PCRwX means PCV2 positive piglets by PCR at week X 7 
PCRXS means PCV2 positive sows by PCR at week X 8 
Pig V and Pig NV mean vaccinated and non-vaccinated piglets, respectively. 9 
Sow V and Sow NV mean vaccinated and non-vaccinated sows, respectively. 10 
The 1
st
 dimension (X axis) separates PCR positive (X<0) from PCR negative animals (X>0) and the 2
nd
 11 
dimension (Y axis) provides insight into early PCV2 detection by PCR (Y < 0 in the plot). 12 
 13 
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 15 
 16 
 17 
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Figure 2.  1 
 2 
 3 
 4 
Tree dendograma with a classification in 4 clusters 5 
 6 
The first division separates two groups of animals which were associated with the vaccination of the 7 
piglets: in the A group (clusters 1 and 2) there were most of the NV pigs (92%), whereas in the B group 8 
(clusters 3 and 4) most of the V ones (80.5%). 9 
1 2 
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Figure 3.  1 
 2 
 3 
 4 
 5 
 6 
Cluster 4) PCV2 non-infected animals 
with medium and high IPMA titres 
through the trial (mainly from NV-V and 
V-V treatments).  
 n=105 
Cluster 1) PCV2 vireamic piglets with 
increasing antibody levels against this 
virus over the time (mainly NV-NV 
treatment).  
Cluster 2) Animals with late PCV2 
infection as well as seroconversion 
(mostly from V-NV treatment).  
Cluster 3) Animals with a decreasing 
PCV2 antibody titres and rare viremia 
(mainly from V-V treatment).  
n=26 
    
NV-NV NV-V V-NV V-V 
n=75 
 n=93 
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